|
시장보고서
상품코드
2051061
치매 치료제 시장 : 약물 종류별, 적응증별, 투여 경로별, 유통 채널별, 지역별Dementia Drugs Market, By Drug Class, By Indication, By Route of Administration, By Distribution Channel,By Geography |
||||||
치매 치료제 시장은 2026년에 279억 7,000만 달러로 추정되며, 2033년에 449억 1,000만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 7.0%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 279억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.00% | 2033년 시장 규모 예측: | 449억 1,000만 달러 |
치매 치료제 시장의 성장은 전 세계적으로 알츠하이머병 및 기타 치매 환자 증가에 의해 주도되고 있습니다. 치매는 알츠하이머병, 뇌졸중 등 뇌에 영향을 미치는 질환으로 인해 발생하는 증후군입니다. 사고, 기억, 추론 등 인지기능의 점진적인 저하가 특징입니다. 치매 진단에 대한 인식이 높아지고 치료법이 다양해지면서 치매 증상에 대한 의료적 도움을 찾는 사람들이 늘고 있습니다. 많은 제약회사들이 치매의 진행을 늦추거나 막을 수 있는 효과적인 약물의 연구개발에 많은 투자를 하고 있습니다.
시장 역학
치매 치료제 시장의 성장은 주로 전 세계 인구의 고령화에 의해 주도되고 있으며, 이로 인해 신경 퇴행성 질환의 위험이 증가하고 있습니다. 개발도상국의 의료비 지출 증가와 바이오제약 기업들의 활발한 연구개발 활동도 시장 확대에 기여하고 있습니다. 하지만, 특히 후기 임상시험에서 많은 후보분자의 실패와 이들 질환의 복잡성으로 인한 높은 의약품 개발 비용이 큰 문제점으로 대두되고 있습니다. 최근 단순히 증상을 완화하는 것뿐만 아니라 질병의 병인에 작용하는 것을 목적으로 하는 질환 개량신약이 승인된 것은 제약기업에게 큰 기회로 작용하고 있습니다. 치매 연구에 대한 정부의 지원과 자금 지원의 증가는 시장 진입 기업들이 혁신을 통해 새로운 치료법을 개발할 수 있는 동력을 제공하고 있습니다. 인구통계학적 변화에 따라 치매 유병률이 지속적으로 증가함에 따라 효과적인 치료법에 대한 수요가 확대될 것으로 예상되며, 시장은 큰 진전을 이룰 것으로 예상됩니다.
본 조사의 주요 특징
이 보고서는 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 예측 기간(2026-2033년)의 CAGR%를 제시하는 세계 치매 치료제 시장에 대한 상세한 분석을 제공합니다.
이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
이 조사는 다음과 같은 매개 변수를 기반으로 세계 치매 치료제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
본 조사에 포함된 주요 기업으로는 Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd가 포함됩니다.
이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있도록 도와줄 것입니다.
세계 치매 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 치매 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것으로 보입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 치매 치료제 시장 : 약물 종류별, 2021-2033년
제5장 치매 치료제 시장 : 적응증별, 2021-2033년
제6장 치매 치료제 시장 : 투여 경로별, 2021-2033년
제7장 치매 치료제 시장 : 유통 채널별, 2021-2033년
제8장 치매 치료제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌과 조사 방법
KSM 26.06.16Dementia Drugs Market is estimated to be valued at USD 27.97 Bn in 2026 and is expected to reach USD 44.91 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 27.97 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 44.91 Bn |
Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.
Market Dynamics
Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.
Key features of the study
This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market
Market Segmentation
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2033)
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitor
- Others
- By Indication Insights (Revenue, USD Bn, 2019 - 2033)
- Alzheimer's Disease Dementia
- Lewy Body Dementia
- Parkinson Disease Dementia
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2033)
- Oral
- Intravenous
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Biogen
- Eisai Co., Ltd.
- Novartis AG
- Cipla
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mapi-Pharma Ltd.
- AbbVie, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Hoffmann-La Roche Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Dementia Drugs Market, By Drug Class
- Dementia Drugs Market, By Indication
- Dementia Drugs Market, By Route of Administration
- Dementia Drugs Market, By Distribution Channel
- Dementia Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Dementia Drugs Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- MAO Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Glutamate Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Dementia Drugs Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Alzheimer's Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Lewy Body Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parkinson Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Dementia Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Dementia Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Dementia Drugs Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mapi-Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- DAIICHI SANKYO COMPANY, LIMITED.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F.Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
